Project Grant R01CA293906
Award Date
4/25/25
Completion Date
3/31/30
Dollars Obligated
$631K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This $380,337 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the University of Washington's efforts to develop predictive models that relate mRNA sequence to stability and translation. The goal is to build an in silico platform to design optimal mRNA sequences for cancer immunotherapy applications. The university will use massively parallel reporter assays to interrogate 5'UTRs, coding sequences, and 3'UTRs, and then leverage machine...
This $457,390 Project Grant award from the National Science Foundation's (NSF) Division of Materials Research aims to develop a new mRNA delivery system based on functional phosphoserine (PS) lipids. The award will support research to understand the targeted and immunomodulatory properties of these zwitterionic functional materials for mRNA delivery, with potential applications in gene therapy, protein-replacement therapy, and cancer immunotherapy. Key objectives include enhancing mRNA...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $427,095.00 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology for generating and analyzing a 3D biomimetic multicellular immunogenic tumor model. The key objectives are to: 1) establish multiple levels of hypoxia within the tumor model, 2) investigate spatiotemporal interactions between the tumor...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) totaling $662,037 supports a neoadjuvant immunotherapy platform study to investigate mechanisms of response in hepatocellular carcinoma (HCC). The primary objectives are to: Utilize high-parameter multiplex imaging mass cytometry to determine the additive effects of combining nivolumab (anti-PD-1) with cabozantinib and relatlimab (anti-LAG3) on immune cell density and...
This Project Grant award of $547,945.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the pathogenesis of immune checkpoint inhibitor (ICI)-induced myocarditis at The Johns Hopkins University. The key objectives are to: Examine how biological factors such as prior cardiac injury, age, and sex influence the risk and severity of ICI-myocarditis by modulating autoreactive, tissue-resident memory T (TRM) cells specific to cardiac...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $657,934 to The Johns Hopkins University to develop a more precise and broadly applicable neoantigen prediction algorithm by integrating multi-omic data. The 5-year project, beginning on April 1, 2025, aims to create a public dataset of immunologically assessed neoantigens with patient-matched multi-omic sequence data, and to develop a novel deep learning-based...
This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $654,681 to Case Western Reserve University to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The key objectives are: 1) to design and develop multifunctional ionizable ELNP based peptide vaccines for effective PDAC immunotherapy; 2) to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $375,134 to the University of Colorado-Denver to investigate a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can tighten healthy tissues, thereby limiting nanoparticle deposition and associated toxicity, while enabling improved delivery to tumors. The research...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is supporting research to investigate how immunotherapy alters cellular communication networks in pancreatic ductal adenocarcinoma (PDAC). The $138,742 award to The Johns Hopkins University will utilize single-cell RNA sequencing data to develop statistical methods for identifying cellular interactions that differ between immunotherapy treatment groups. Additionally, the...